If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Almost every article that describes the incidence of multiple sclerosis (MS) over
various epochs suggests that it is rising and that the incremental rates are higher
for women than men. In recent years the claim for increasing MS incidence is particularly
notable for inhabitants of the Middle East (
). In general, there is adjustment for population size, age and gender and sometimes
for migration in or out of the relevant area. But what about other confounders? There
has been significantly increased awareness of MS over the past 30 years particularly
following the introduction of MRI and disease modifying treatment (DMT). Such heightened
recognition may be gauged by the number of MS-related articles cited in PubMed (Fig. 1). The graph shows that the rate of MS citations has approximately doubled every 10
years. This increased awareness will filter through to clinicians, patients and their
families and result in higher referral rates to secondary care centres.
Fig. 1Serial trends in publications related to MS as listed in PubMed 1970-2020. Note: the
data for 2020 are not yet complete.
Christopher H Hawkes: Joint Chief Editor of Multiple Sclerosis and Related Disorders.
Biography
Gavin Giovannoni: Over the last 5 years, Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to multiple sclerosis clinical trial design, trial steering committees and data and safety monitoring committees from Abbvie, Actelion, Atara Bio, Biogen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Japanese Tobacco, Merck KGAa, Novartis, Roche, Sanofi-Genzyme and Teva. Professor Giovannoni is and editor of Multiple Sclerosis and Related Disorders and chairs the MS Brain Health initiative, MS Academy and triMS.online conference. He has previously been a member of the multiple sclerosis and related disorders specialist advisory group of the Association of British Neurologists and an ECTRIMS representative. He is a director of Oxford Health Policy Forum, a non-profit social enterprise.
Biography
Jeanette Lechner-Scott: has accepted travel compensation from Novartis, Biogen, Roche and Merck. Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Biogen, Merck, Roche, TEVA and Novartis.
Biography
Michael Levy: has received consulting fees from Alexion, Viela Bio and Genentech/Roche/Chugai. In addition, he has received consulting fees from Quest Diagnostics and UCB Pharmaceuticals.
